Tag - Myomo

Myomo, Inc. to Report Second Quarter 2017 Results on August 14, 2017

Ziad2022-11-25T14:05:30-05:00Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a commercial stage medical robotics company, today announced that it will release its unaudited financial results for the quarter ended June 30, 2017 on Monday, August 14, 2017, after the US markets close. Read more >>

Myomo, Inc. Obtains CE Mark Approval for MyoPro®

Ziad2022-11-25T14:05:40-05:00Myomo, Inc. (NYSE MKT:MYO) (“Myomo” or the “Company”), a commercial stage medical robotics company, today announced that it has obtained CE Mark approval for commercial sale of its next-generation MyoPro myoelectric arm orthosis across the European Economic Area (EEA). The CE Mark indicates MyoPro complies with the essential requirements of relevant EU legislation and has achieved quality system certification. MyoPro is the only lightweight wearable device that can restore function in the paralyzed or weakened arms and hands of individuals...

Myomo Expands Management Team to Accelerate Commercialization of MyoPro® Powered Orthosis

Ziad2022-11-25T14:05:41-05:00Myomo®, Inc. (NSYE MKT: MYO), a commercial stage medical robotics company, today announced the expansion of its management team with three new full-time positions in medical affairs, sales and marketing. The expansion marks the company’s accelerated commercialization of its MyoPro line of powered orthoses after raising growth capital through its IPO in June 2017. Read more >>

Myomo announces center of excellence program

Ziad2022-11-25T14:05:41-05:00Myomo Inc., a medical robotics company, has created a new program to partner with O&P clinics in the United States to provide joint marketing and training for the MyoPro line of powered orthoses, according to a company press release. Read more >>

Robotics Maker CEO Paul Gudonis Explains How Myomo, Inc. Turned Regulation A+ Equity Crowdfunding Into a NYSE Listing

Ziad2022-11-25T14:05:41-05:00In this podcast, Myomo CEO Paul Gudonis provides his insight on his company’s experience with Reg.A+, from the initial stages to their successful and impressive listing on the NYSE. Mr. Gudonis touches on some extremely important points that anyone in the Regulation A+ realm should know and the advice he gives to potential Reg.A+ issuers is invaluable. Read more >>

Chardon company makes MyoPro brace that helps paralyzed arms function again (video)

Ziad2022-11-25T14:05:41-05:00MyoPro, developed by Cambridge, Massachusetts-based Myomo Inc., allows patients with partially paralyzed or weakened arms and hands to return to work, do everyday tasks and reduce medical care costs, Myomo said in a statement. The technology could help patients who have suffered strokes, spinal cord or nerve injuries, and people with amyotrohic lateral sclerosis (ALS) or multiple sclerosis. Read more >>

Myomo Announces Publication Of Significant Clinical Research

Ziad2022-11-25T14:05:41-05:00Myomo, Inc. (NYSE MKT: MYO) (“Myomo” or the “Company”), a commercial stage medical robotics company, today announced publication of an investigator-led clinical study in the Archives of Physical Medicine and Rehabilitation. Read more >>

Paul Gudonis (CEO Of Myomo)

Ziad2022-11-25T14:05:41-05:00Paul Gudonis (CEO Of Myomo) by The Financial Exchange transcript. Read more >>

Myomo (MYO) Reports Publication of Significant Clinical Research

Ziad2022-11-25T14:05:41-05:00Myomo, Inc. (NYSE MKT: MYO) (“Myomo” or the “Company”), a commercial stage medical robotics company, today announced publication of an investigator-led clinical study in the Archives of Physical Medicine and Rehabilitation. Read more >>

VIA Folio Processes Closing for Myomo, the First Exchange-Traded Reg A+ IPO

Ziad2022-11-25T14:05:41-05:00VIA Folio is pleased to announce that it has processed the closing of Myomo's Reg A+ IPO, the first of its kind to be traded on a national exchange. Read more >>